Document is current
Any future updates will be listed below
-
Authors
Singh, Balwinder
Ho, Ada Man-Choi
Coombes, Brandon J.
Romo-Nava, Francisco
Bond, David J.
Veldic, Marin
Pendegraft, Richard S.
Batzler, Anthony
Cuellar-Barboza, Alfredo B.
Gardea-Reséndez, Manuel
Prieto, Miguel L.
Ozerdem, Aysegul
McElroy, Susan L.
Biernacka, Joanna M.
Frye, Mark A.
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (KL2 TR002379)
- License Information
-
More Information
Article History
Received: 1 August 2025
Accepted: 30 November 2025
First Online: 8 December 2025
Declarations
:
: Ethics approval for The Mayo Clinic Bipolar Disorder Biobank has been obtained from the Mayo Clinic Institutional Review Board (reference ID: 08-008794). Written informed consent was obtained from all participants.
: Not applicable.
: MAF received grant support from Assurex Health and Mayo Foundation, received CME travel and honoraria from Carnot Laboratories and American Physician Institute, and has Financial Interest/Stock ownership/Royalties from Chymia LLC. SLM is a consultant to, or member of the scientific advisory boards of, in the past year: Axsome, Idorsia, Levo, Kallyope, MycoMedica, Novo Nordisk, Otsuka, and Soleno. SLM is presently or has been in the past year a principal or co-investigator on research studies sponsored by: Axsome, Idorsia, Marriott Foundation, National Institute of Mental Health, Novo Nordisk, and Otsuka. Patents: SLM is also inventor on United States Patent No. 6,323,236 B2, Use of Sulfamate Derivatives for Treating Impulse Control Disorders, and, along with the patent’s assignee, University of Cincinnati, Cincinnati, OH, has received payments from Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has exclusive rights under the patent. FRN is supported in part by NIMH grants K23MH120503 and 1R61MH133770-01A1; is the inventor on a U.S. Patent and Trademark Office patent # 10,857,356. MGR receives research support from Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT) in Mexico. BS reports research grant support from the Mayo Clinic, the National Network of Depression Centers, and Breakthrough Discoveries for Thriving with Bipolar Disorder (BD2). He is a KL2 Mentored Career Development Program scholar, supported by CTSA Grant Number KL2 TR002379 from the National Center for Advancing Translational Science (NCATS). He has received honoraria (to Mayo Clinic) from Elsevier for editing a Clinical Overview on Treatment-Resistant Depression. The rest of the co-authors have no conflict of interest to declare.
